Cargando…

A Progressively Disassembled DNA Repair Inhibitors Nanosystem for the Treatment of BRCA Wild-Type Triple-Negative Breast Cancer

BACKGROUND: Olaparib, a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor has demonstrated promising efficacy in patients with triple-negative breast cancer (TNBC) carrying breast cancer gene (BRCA) mutations. However, its impact on BRCA wild-type (BRCAwt) TNBC is limited. Hence, it is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Weimin, Wang, Jinghao, Ma, Xiaocong, Shao, Ni, Ye, Kunlin, Zhang, Dong, Shi, Changzheng, Luo, Liangping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612513/ https://www.ncbi.nlm.nih.gov/pubmed/37901361 http://dx.doi.org/10.2147/IJN.S426639

Ejemplares similares

Designing multifunctional cancer-targeted nanosystem for magnetic resonance molecular imaging-guided theranostics of lung cancer
por: Gao, Peng, et al.
Publicado: (2018)

Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models
por: Sambade, Maria J, et al.
Publicado: (2019)

BRCA2 Mutations and Triple-Negative Breast Cancer
por: Meyer, Peter, et al.
Publicado: (2012)

Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem
por: Ferraro, Maria Grazia, et al.
Publicado: (2023)

A paclitaxel and microRNA-124 coloaded stepped cleavable nanosystem against triple negative breast cancer
por: Chen, Chuanrong, et al.
Publicado: (2021)

BRCA1 mutation in the Triple- Negative Breast Cancer Group
por: Maksimenko, Jelena, et al.
Publicado: (2012)

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
por: Glodzik, Dominik, et al.
Publicado: (2020)

Polysaccharide Nanosystems for Future Progress in Cardiovascular Pathologies
por: Silva, Amanda Karine Andriola, et al.
Publicado: (2014)

Progress and Hurdles of Therapeutic Nanosystems against Cancer
por: Martín-Contreras, Marina, et al.
Publicado: (2022)

Progress in Diamanes and Diamanoids Nanosystems for Emerging Technologies
por: Tiwari, Santosh K., et al.
Publicado: (2022)

The role of BRCA status on prognosis in patients with triple-negative breast cancer
por: Xie, Yuxin, et al.
Publicado: (2017)

Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis
por: Pogoda, Katarzyna, et al.
Publicado: (2020)

Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer
por: Ye, Fugui, et al.
Publicado: (2021)

The Carboxyl Terminus of Brca2 Links the Disassembly of Rad51 Complexes to Mitotic Entry
por: Ayoub, Nabieh, et al.
Publicado: (2009)

A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2
por: Kitahara, Miyuki, et al.
Publicado: (2021)

Albumin-based nanosystem for dual-modality imaging-guided chem-phototherapy against immune-cold triple-negative breast cancer
por: Peng, Chen, et al.
Publicado: (2023)

Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer
por: MAKSIMENKO, JELENA, et al.
Publicado: (2014)

Comparison of BRCA1 Expression between Triple-Negative and Luminal Breast Tumors
por: Darbeheshti, Farzaneh, et al.
Publicado: (2018)

Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer
por: Emborgo, Trisha S, et al.
Publicado: (2020)

Influence of Germline BRCA Genotype on the Survival of Patients with Triple-Negative Breast Cancer
por: Villarreal-Garza, Cynthia, et al.
Publicado: (2021)

Risk of metastasis in BRCA2 carriers diagnosed with triple‐negative breast cancer
por: Moreno, Marcelo, et al.
Publicado: (2023)

Facile synthesis of near-infrared responsive on-demand oxygen releasing nanoplatform for precise MRI-guided theranostics of hypoxia-induced tumor chemoresistance and metastasis in triple negative breast cancer
por: Zhang, Dong, et al.
Publicado: (2022)

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
por: Bouwman, Peter, et al.
Publicado: (2010)

Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients With Triple-Negative Breast Cancer
por: Huang, Xin, et al.
Publicado: (2020)

Immunomodulatory Nanosystems
por: Feng, Xiangru, et al.
Publicado: (2019)

miR-638 mediated regulation of BRCA1affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer
por: Tan, Xiaohui, et al.
Publicado: (2014)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion
por: Bogan, Danielle, et al.
Publicado: (2017)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

The prevalence of BRCA1/2 mutations of triple-negative breast cancer patients in Xinjiang multiple ethnic region of China
por: Li, Yong Tao, et al.
Publicado: (2014)

FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair
por: Wang, Shu-Ping, et al.
Publicado: (2021)

Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple‐negative breast cancer cohort
por: Liu, Xiaoran, et al.
Publicado: (2017)

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
por: Young, SR, et al.
Publicado: (2009)

Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia
por: PALOMBA, GRAZIA, et al.
Publicado: (2014)

BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
por: Blanchard, Zannel, et al.
Publicado: (2015)

Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis
por: Chen, Haixia, et al.
Publicado: (2018)

Triple-negative Breast Cancer Arising in a Fibroadenoma in BRCA 1 Mutated Patient
por: Brunetti, Nicole, et al.
Publicado: (2022)

Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
por: Tung, Nadine, et al.
Publicado: (2010)

BRCA2-HSF2BP oligomeric ring disassembly by BRME1 promotes homologous recombination
por: Ghouil, Rania, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dgl3ouad63bno7rvd1d5rolver